SAN DIEGO--(BUSINESS WIRE)--Jan. 26, 2018--
Illumina, Inc. (NASDAQ: ILMN) announced today that a federal jury in San
Francisco has ruled in its favor in a patent infringement suit filed
against Ariosa Diagnostics, Inc., now owned by Roche.
The jury found that both Ariosa’s previous and current version of the
Harmony non-invasive prenatal test (NIPT) infringe US Patent 8,318,430
and US Patent 7,955,794. The jury awarded Illumina approximately $26.7
million for past damages.
The jury rejected counterclaims by Ariosa that Illumina had breached a
supply agreement between the companies by bringing the lawsuit.
The US Patent and Trademark Office previously upheld the validity of the
patents rejecting multiple challenges filed by Ariosa.
“We are pleased with the outcome reached by the jury,” said Charles
Dadswell, Senior Vice President and General Counsel for Illumina. “This
verdict again validates these patents, the hard work and ingenuity of
the inventors, and their significant contribution to the field of NIPT.”
Illumina intends to seek injunctive relief for ongoing infringement by
Ariosa’s continuing sale of its Harmony test.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
View source version on businesswire.com: http://www.businesswire.com/news/home/20180126005640/en/
Source: Illumina, Inc.
Jacquie Ross, CFA